Publicaciones en colaboración con investigadores/as de Rush University Medical Center (35)

2024

  1. Development and external validation of the 'Global Surgical-Site Infection' (GloSSI) predictive model in adult patients undergoing gastrointestinal surgery

    British Journal of Surgery, Vol. 111, Núm. 6

  2. Ultraprocessed food intake and body mass index change among youths: a prospective cohort study

    American Journal of Clinical Nutrition, Vol. 120, Núm. 4, pp. 836-845

2023

  1. An International Expert Delphi Consensus on Defining Textbook Outcome in Liver Surgery (TOLS)

    Annals of Surgery, Vol. 277, Núm. 5, pp. 821-828

  2. Editorial: Nutrition and neurodegenerative diseases: insights and perspectives on prevention strategies

    Frontiers in Nutrition

  3. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma: Final Data from the Phase 2 ELOQUENT-3 Trial

    HemaSphere, Vol. 7, Núm. 3, pp. E843

2022

  1. Melphalan flufenamide for relapsed/refractory multiple myeloma

    Drugs of today (Barcelona, Spain : 1998), Vol. 58, Núm. 8, pp. 407-423

  2. Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

    British Journal of Haematology, Vol. 196, Núm. 3, pp. 639-648

2021

  1. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 7, pp. 757-767

2020

  1. Imaging-AMARETTO: An imaging genomics software tool to interrogate multiomics networks for relevance to radiography and histopathology imaging biomarkers of clinical outcomes

    JCO Clinical Cancer Informatics, Vol. 4, pp. 421-435

  2. Melflufen for relapsed and refractory multiple myeloma

    Expert Opinion on Investigational Drugs, Vol. 29, Núm. 10, pp. 1069-1078

2019

  1. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Clinical Trial

    JAMA Psychiatry, Vol. 76, Núm. 9, pp. 893-903

  2. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of keynote-010 trial

    Annals of Oncology, Vol. 30, Núm. 2, pp. 281-289

2018

  1. Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests

    Movement Disorders, Vol. 33, Núm. 11, pp. 1750-1759

  2. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients

    Parkinsonism and Related Disorders, Vol. 52, pp. 83-89

2017

  1. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration

    Movement Disorders Clinical Practice, Vol. 4, Núm. 4, pp. 536-544

  2. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update

    The Lancet Neurology, Vol. 16, Núm. 3, pp. 238-250

2016

  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial

    The Lancet, Vol. 387, Núm. 10027, pp. 1540-1550

2015

  1. Convergent genetic and expression data implicate immunity in Alzheimer's disease

    Alzheimer's and Dementia, Vol. 11, Núm. 6, pp. 658-671

  2. Genome-wide meta-analysis on the sense of smell among US older adults

    Medicine (United States), Vol. 94, Núm. 47, pp. e1892

2014

  1. Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease

    PLoS ONE, Vol. 9, Núm. 6